Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Assets (2021 - 2025)

Historic Assets for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $1.3 billion.

  • Krystal Biotech's Assets rose 2632.56% to $1.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year increase of 2632.56%. This contributed to the annual value of $1.3 billion for FY2025, which is 2632.56% up from last year.
  • According to the latest figures from Q4 2025, Krystal Biotech's Assets is $1.3 billion, which was up 2632.56% from $1.2 billion recorded in Q3 2025.
  • Over the past 5 years, Krystal Biotech's Assets peaked at $1.3 billion during Q4 2025, and registered a low of $443.0 million during Q1 2021.
  • For the 5-year period, Krystal Biotech's Assets averaged around $786.9 million, with its median value being $737.2 million (2023).
  • Its Assets has fluctuated over the past 5 years, first plummeted by 1378.35% in 2023, then soared by 6044.01% in 2024.
  • Krystal Biotech's Assets (Quarter) stood at $626.3 million in 2021, then fell by 10.83% to $558.4 million in 2022, then skyrocketed by 46.54% to $818.4 million in 2023, then grew by 29.02% to $1.1 billion in 2024, then rose by 26.33% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q4 2025, $1.2 billion for Q3 2025, and $1.1 billion during Q2 2025.